Investigating how imaging and blood tests can predict responses to lung cancer treatments
Biomarkers of Response to Immuno-chemotherapy & oliGometastatic Hypofractionated radioTherapy (BRIGHT) for Lung Cancer: Synergy of PET/CT Imaging and Peripheral Blood Assays
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-10992106
This study is looking at how well patients with advanced lung cancer respond to a mix of chemotherapy and immunotherapy by using special imaging and blood tests, with the goal of personalizing treatments to help improve survival and reduce side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10992106 on ClinicalTrials.gov |
What this research studies
This research focuses on improving treatment outcomes for patients with metastatic non-small cell lung cancer (NSCLC) by using advanced imaging techniques and blood tests to identify how well patients respond to combined therapies of chemotherapy and immunotherapy. The study aims to assess treatment responses through positron emission tomography (PET) imaging and the analysis of circulating biomarkers in the blood. By understanding these responses, the research seeks to tailor treatments more effectively, potentially leading to better survival rates and reduced side effects for patients. The approach emphasizes precision medicine, aiming to select the right treatment for the right patient at the right time.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with newly diagnosed metastatic non-small cell lung cancer who are starting standard chemotherapy and immunotherapy treatments.
Not a fit: Patients with early-stage lung cancer or those who have not been diagnosed with metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for lung cancer patients, improving survival rates and minimizing unnecessary side effects.
How similar studies have performed: Previous research has shown promising results in using imaging and biomarkers to guide treatment decisions in cancer therapy, indicating that this approach has potential for success.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BOWEN, STEPHEN R. — UNIVERSITY OF WASHINGTON
- Study coordinator: BOWEN, STEPHEN R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.